All three Galenika bids flawed – Bidders to amend the documents by August 16

Source: eKapija Wednesday, 03.08.2016. 08:33
Comments
Podeli
(Photo: galenika.rs)
The documentation submitted by the three bidders at the tender for the purchase of a 25% share of Galenika contains certain flaws, the Commission responsible for carrying out the strategic partnership procedure has determined and set the deadline for August 16 for amending the documents.

After the deadline expires, the Commission will open the financial bids of those bidders which submit the documentation in line with the rules of the strategic partnership procedure, the Ministry of Economy reports.

After determining the validity of the submitted amended documentation and opening the financial bids, the Commission prepares the ranking list. The final ranking list, as they explain, is adopted by the Government of Serbia, which also pronounces the best bidder.

The negotiations with the top ranked bidder last for 90 days at most.


The Commission considered the report on the analysis of the documentation submitted by all three bidders, Cadila Pharmaceuticals Limited from India, EMS S.A. from Brazil and the Consortium Frontier Phrama Limited from Great Britain and LLC NPA Petrovax Pharm from Russia, on August 2, following which it was determined that the flaws are formal in nature.

In line with the Decree on Strategic Partnership, the Commission has set a deadline for all the bidders to amend the documents by August 16, 2016.
Comments
Your comment
Full information is available only to commercial users-subscribers and it is necessary to log in.

Forgot your password? Click here HERE

For free test use, click HERE

Follow the news, tenders, grants, legal regulations and reports on our portal.
Registracija na eKapiji vam omogućava pristup potpunim informacijama i dnevnom biltenu
Naš dnevni ekonomski bilten će stizati na vašu mejl adresu krajem svakog radnog dana. Bilteni su personalizovani prema interesovanjima svakog korisnika zasebno, uz konsultacije sa našim ekspertima.